References: |
1. Egorin, M.J., et al. "Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats." Cancer Chemother. Pharmacol. 49:7-19 (2002). 2. Tian, Z.Q., et al. "Synthesis and biological activities of novel 17-aminogeldanamycin derivatives." Bioorg. Med. Chem. 12:5317-5329 (2004). 3. Kaur, G, et al. "Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator." Clin. Cancer Res. 10:4813-4821 (2004). 4. Bull, E.E., et al. "Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin." Clin. Cancer Res. 10:8077-8084 (2004). 5. Hollingshead, M., et al. "In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative." Cancer Chemother. Pharmacol. 56:115-125 (2005). |